The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
Not yet recruiting
- Conditions
- CLL
- Registration Number
- NCT06557304
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion Criteria:<br><br> 1. Patients aged =18 years old<br><br> 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring<br> treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria);<br><br> 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK<br> inhibitor;<br><br> 4. Prior or current use of BTK inhibitor for =3 months<br><br> 5. At least one follow-up was recorded during BTK inhibitor treatment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival
- Secondary Outcome Measures
Name Time Method Time to Next Therapy (TTNT);Adverse Events